company background image
HLUN B logo

H. Lundbeck CPSE:HLUN B Stock Report

Last Price

kr.37.64

Market Cap

kr.36.1b

7D

2.0%

1Y

4.0%

Updated

14 Jun, 2024

Data

Company Financials +

HLUN B Stock Overview

A biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.

HLUN B fundamental analysis
Snowflake Score
Valuation5/6
Future Growth1/6
Past Performance3/6
Financial Health5/6
Dividends3/6

H. Lundbeck A/S Competitors

Price History & Performance

Summary of all time highs, changes and price drops for H. Lundbeck
Historical stock prices
Current Share Pricekr.37.64
52 Week Highkr.39.82
52 Week Lowkr.30.96
Beta0.16
1 Month Change-0.95%
3 Month Change15.74%
1 Year Change4.04%
3 Year Changen/a
5 Year Changen/a
Change since IPO15.82%

Recent News & Updates

These 4 Measures Indicate That H. Lundbeck (CPH:HLUN B) Is Using Debt Safely

Jun 05
These 4 Measures Indicate That H. Lundbeck (CPH:HLUN B) Is Using Debt Safely

Recent updates

These 4 Measures Indicate That H. Lundbeck (CPH:HLUN B) Is Using Debt Safely

Jun 05
These 4 Measures Indicate That H. Lundbeck (CPH:HLUN B) Is Using Debt Safely

H. Lundbeck (CPH:HLUN B) Will Pay A Larger Dividend Than Last Year At DKK0.70

Mar 07
H. Lundbeck (CPH:HLUN B) Will Pay A Larger Dividend Than Last Year At DKK0.70

H. Lundbeck (CPH:HLUN B) Has Announced That It Will Be Increasing Its Dividend To DKK0.70

Feb 22
H. Lundbeck (CPH:HLUN B) Has Announced That It Will Be Increasing Its Dividend To DKK0.70

H. Lundbeck A/S Just Missed Earnings - But Analysts Have Updated Their Models

Feb 10
H. Lundbeck A/S Just Missed Earnings - But Analysts Have Updated Their Models

Shareholder Returns

HLUN BDK PharmaceuticalsDK Market
7D2.0%0.03%-0.1%
1Y4.0%18.7%36.2%

Return vs Industry: HLUN B underperformed the Danish Pharmaceuticals industry which returned 18.7% over the past year.

Return vs Market: HLUN B underperformed the Danish Market which returned 36.2% over the past year.

Price Volatility

Is HLUN B's price volatile compared to industry and market?
HLUN B volatility
HLUN B Average Weekly Movement3.3%
Pharmaceuticals Industry Average Movement5.2%
Market Average Movement4.3%
10% most volatile stocks in DK Market9.8%
10% least volatile stocks in DK Market2.9%

Stable Share Price: HLUN B has not had significant price volatility in the past 3 months.

Volatility Over Time: HLUN B's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19155,681Charl van Zylwww.lundbeck.com

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company’s principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson’s disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis.

H. Lundbeck A/S Fundamentals Summary

How do H. Lundbeck's earnings and revenue compare to its market cap?
HLUN B fundamental statistics
Market capkr.36.14b
Earnings (TTM)kr.2.42b
Revenue (TTM)kr.20.16b

15.5x

P/E Ratio

1.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HLUN B income statement (TTM)
Revenuekr.20.16b
Cost of Revenuekr.4.45b
Gross Profitkr.15.70b
Other Expenseskr.13.29b
Earningskr.2.42b

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Aug 21, 2024

Earnings per share (EPS)2.44
Gross Margin77.91%
Net Profit Margin11.99%
Debt/Equity Ratio16.6%

How did HLUN B perform over the long term?

See historical performance and comparison

Dividends

1.9%

Current Dividend Yield

29%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.